State of the art in anti-cancer mAbs

Autores
Chiavenna, Sebastián Matias; Jaworski, Juan Pablo; Vendrell, Alejandrina
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
Instituto de Virología
Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fuente
Journal of biomedical science (2017) : 24:15
Materia
Neoplasmas
Anticuerpos Monoclonales
Inmunoterapia
Neoplasms
Monoclonal Antibodies
Immunotherapy
Cáncer (Enfermedad)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/548
Acceder
id INTADig_c446260b80c6bfec7c6e8b82f1ebc492
oai_identifier_str oai:localhost:20.500.12123/548
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling State of the art in anti-cancer mAbsChiavenna, Sebastián MatiasJaworski, Juan PabloVendrell, AlejandrinaNeoplasmasAnticuerpos MonoclonalesInmunoterapiaNeoplasmsMonoclonal AntibodiesImmunotherapyCáncer (Enfermedad)Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.Instituto de VirologíaFil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; EspañaFil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina2017-07-03T15:04:59Z2017-07-03T15:04:59Z2017-02-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/548https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y1423-0127https://doi.org/10.1186/s12929-016-0311-yJournal of biomedical science (2017) : 24:15reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-29T13:44:06Zoai:localhost:20.500.12123/548instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:44:06.472INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv State of the art in anti-cancer mAbs
title State of the art in anti-cancer mAbs
spellingShingle State of the art in anti-cancer mAbs
Chiavenna, Sebastián Matias
Neoplasmas
Anticuerpos Monoclonales
Inmunoterapia
Neoplasms
Monoclonal Antibodies
Immunotherapy
Cáncer (Enfermedad)
title_short State of the art in anti-cancer mAbs
title_full State of the art in anti-cancer mAbs
title_fullStr State of the art in anti-cancer mAbs
title_full_unstemmed State of the art in anti-cancer mAbs
title_sort State of the art in anti-cancer mAbs
dc.creator.none.fl_str_mv Chiavenna, Sebastián Matias
Jaworski, Juan Pablo
Vendrell, Alejandrina
author Chiavenna, Sebastián Matias
author_facet Chiavenna, Sebastián Matias
Jaworski, Juan Pablo
Vendrell, Alejandrina
author_role author
author2 Jaworski, Juan Pablo
Vendrell, Alejandrina
author2_role author
author
dc.subject.none.fl_str_mv Neoplasmas
Anticuerpos Monoclonales
Inmunoterapia
Neoplasms
Monoclonal Antibodies
Immunotherapy
Cáncer (Enfermedad)
topic Neoplasmas
Anticuerpos Monoclonales
Inmunoterapia
Neoplasms
Monoclonal Antibodies
Immunotherapy
Cáncer (Enfermedad)
dc.description.none.fl_txt_mv Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
Instituto de Virología
Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
description Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
publishDate 2017
dc.date.none.fl_str_mv 2017-07-03T15:04:59Z
2017-07-03T15:04:59Z
2017-02-20
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
status_str publishedVersion
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/548
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y
1423-0127
https://doi.org/10.1186/s12929-016-0311-y
url http://hdl.handle.net/20.500.12123/548
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y
https://doi.org/10.1186/s12929-016-0311-y
identifier_str_mv 1423-0127
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Journal of biomedical science (2017) : 24:15
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619114683826176
score 12.558318

Publicaciones similares